LOS ANGELES, Dec. 14, 2015 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced the establishment of an agreement with a major Canadian
cancer cooperative group, The Canadian Brain Tumour Consortium
(CBTC), for the phase 3 registrational trial of its cancer
immunotherapy ICT-107 in patients with newly diagnosed
glioblastoma. Established in 1998, and including a national
investigator network of over 100 brain tumor specialists and
researchers, the CBTC partners with industry to evaluate and
execute clinical trials of promising new agents in a timely and
cost-effective manner. The CBTC's major goals are furthering brain
tumor research and development and supporting patients and their
families who are affected by glioblastoma.
Andrew Gengos, ImmunoCellular
Chief Executive Officer, commented: "Partnering with the highly
respected CBTC is a critical component of our clinical trial
infrastructure, and further strengthens the multi-national clinical
trial network for our ICT-107 phase 3 trial. With complementary
collaborations in place with cooperative groups in the US and,
Europe, the CBTC collaboration can
enable us to execute this international clinical program in a high
quality and efficient manner. As the lead asset in our cancer
immunotherapy pipeline, we believe that ICT-107 represents a
valuable opportunity for ImmunoCellular. As the phase 3 program
progresses, we also intend to continue to build our cancer
immunotherapy platform, including our Stem-to-T-cell program, with
the goal of expanding our anti-cancer technological and therapeutic
approaches."
The ICT-107 phase 3 registrational trial is open for enrollment
in the US with additional sites anticipated to open in Canada and Europe in the coming weeks and months.
About the CBTC
The Canadian Brain Tumour Consortium (CBTC) creates value for
its members, the industry and various cooperative groups by
existing as a national investigator network of over 100 brain
tumour specialists and researchers treating both pediatric and
adult patients with brain tumour. The goal of the CBTC is to
develop and promote multi-centre brain tumour research projects in
Canada. The CBTC was established
in 1998 and became a non-profit corporation in 1999. A
professional, business-like approach enables the CBTC to partner
effectively with industry to evaluate and execute clinical trials
of promising new agents in a timely and cost-effective manner. By
drawing together experts from across the country along with large
patient pools, the CBTC can carry out large-scale, independent
research studies not easily conquered by any single centre. For
more information, please visit: http://www.cbtc.ca/index.htm.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. The phase 3 registrational trial of lead product
candidate, ICT-107, a dendritic cell-based immunotherapy targeting
multiple tumor-associated antigens on glioblastoma stem cells, is
open for patient enrollment. ImmunoCellular's pipeline also
includes: ICT-121, a dendritic cell immunotherapy targeting the
CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a
dendritic cell immunotherapy targeting antigens on ovarian cancer
stem cells; and the Stem-to-T-cell research program which engineers
the patient's hematopoietic stem cells to generate antigen-specific
cancer-killing T cells. To learn more about ImmunoCellular, please
visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements,
including statements regarding the development and
commercialization of ICT-107, initiation of a phase 3 study of
ICT-107 and the potential to accelerate the study through the
relationship with the CBTC, the advancement of the ICT-121 phase 1
trial, the development of our preclinical Stem-to-T-cell program
and our ability to achieve our other clinical, operational and
financial goals. These statements are based on ImmunoCellular's
current expectations and involve significant risks and
uncertainties, including those described under the heading "Risk
Factors" in ImmunoCellular's most recently filed quarterly report
on Form 10-Q and annual report on Form 10-K. Except as required by
law, ImmunoCellular undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-establishes-agreement-with-the-canadian-brain-tumour-consortium-for-ict-107-phase-3-registrational-trial-in-glioblastoma-300191524.html
SOURCE ImmunoCellular Therapeutics, Ltd.